Syndax Pharmaceuticals, Inc. Research and Development Expense
Syndax Pharmaceuticals, Inc. (SNDX) reported Research and Development Expense of $68.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $68.04M, a 9.34% increase year-over-year.
- Syndax Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $58.84M, a 4.53% decline year-over-year.
- Syndax Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $78.64M, a 20.01% increase year-over-year.
- Syndax Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $56.28M, a 20.70% decline year-over-year.
- Syndax Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $258.78M, a 7.09% increase from fiscal 2024.
- Syndax Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $241.65M, a 48.22% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $163.03M, a 37.58% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $118.50M, a 34.28% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $68.04M 10-Q · filed 2026-08-04 | $126.88M 10-Q · filed 2026-08-04 | $205.52M derived: sum of 3 quarters · filed 2026-08-04 | $261.80M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $58.84M 10-Q · filed 2026-04-30 | $137.49M derived: sum of 2 quarters · filed 2026-04-30 | $193.77M derived: sum of 3 quarters · filed 2026-04-30 | $255.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $78.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $134.92M derived: sum of 2 quarters · filed 2026-02-26 | $197.15M derived: sum of 3 quarters · filed 2026-08-04 | $258.78M 10-K · filed 2026-02-26 |
| 2025-09-30 | $56.28M 10-Q · filed 2025-11-03 | $118.51M derived: sum of 2 quarters · filed 2026-08-04 | $180.14M 10-Q · filed 2025-11-03 | $245.67M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $62.23M 10-Q · filed 2026-08-04 | $123.86M 10-Q · filed 2026-08-04 | $189.39M derived: sum of 3 quarters · filed 2026-08-04 | $260.36M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $61.64M 10-Q · filed 2026-04-30 | $127.17M derived: sum of 2 quarters · filed 2026-04-30 | $198.14M derived: sum of 3 quarters · filed 2026-04-30 | $246.79M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $65.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $136.50M derived: sum of 2 quarters · filed 2026-02-26 | $185.16M derived: sum of 3 quarters · filed 2026-02-26 | $241.65M 10-K · filed 2026-02-26 |
| 2024-09-30 | $70.97M 10-Q · filed 2025-11-03 | $119.63M derived: sum of 2 quarters · filed 2025-11-03 | $176.12M 10-Q · filed 2025-11-03 | $231.24M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $48.66M 10-Q · filed 2025-08-04 | $105.15M 10-Q · filed 2025-08-04 | $160.27M derived: sum of 3 quarters · filed 2026-02-26 | $199.36M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $56.49M 10-Q · filed 2025-05-05 | $111.62M derived: sum of 2 quarters · filed 2026-02-26 | $150.71M derived: sum of 3 quarters · filed 2026-02-26 | $185.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $55.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $94.21M derived: sum of 2 quarters · filed 2026-02-26 | $128.98M derived: sum of 3 quarters · filed 2026-02-26 | $163.03M 10-K · filed 2026-02-26 |
| 2023-09-30 | $39.09M 10-Q · filed 2024-11-05 | $73.85M derived: sum of 2 quarters · filed 2024-11-05 | $107.91M 10-Q · filed 2024-11-05 | $139.75M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $34.76M 10-Q · filed 2024-08-01 | $68.82M 10-Q · filed 2024-08-01 | $100.66M derived: sum of 3 quarters · filed 2025-03-03 | $127.56M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $34.05M 10-Q · filed 2024-05-08 | $65.89M derived: sum of 2 quarters · filed 2025-03-03 | $92.80M derived: sum of 3 quarters · filed 2025-03-03 | $122.53M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $31.84M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $58.74M derived: sum of 2 quarters · filed 2025-03-03 | $88.48M derived: sum of 3 quarters · filed 2025-03-03 | $118.50M 10-K · filed 2025-03-03 |
| 2022-09-30 | $26.90M 10-Q · filed 2023-11-02 | $56.63M derived: sum of 2 quarters · filed 2023-11-02 | $86.66M 10-Q · filed 2023-11-02 | $110.56M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $29.73M 10-Q · filed 2023-08-03 | $59.76M 10-Q · filed 2023-08-03 | $83.66M derived: sum of 3 quarters · filed 2024-02-27 | $109.26M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $30.02M 10-Q · filed 2023-05-08 | $53.92M derived: sum of 2 quarters · filed 2024-02-27 | $79.53M derived: sum of 3 quarters · filed 2024-02-27 | $96.40M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $23.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $49.51M derived: sum of 2 quarters · filed 2024-02-27 | $66.38M derived: sum of 3 quarters · filed 2024-02-27 | $88.25M 10-K · filed 2024-02-27 |
| 2021-09-30 | $25.61M 10-Q · filed 2022-11-03 | $42.48M derived: sum of 2 quarters · filed 2022-11-03 | $64.35M 10-Q · filed 2022-11-03 | $79.87M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $16.87M 10-Q · filed 2022-08-08 | $38.74M 10-Q · filed 2022-08-08 | $54.26M derived: sum of 3 quarters · filed 2022-08-08 | $68.67M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $21.87M 10-Q · filed 2022-05-09 | $37.39M derived: sum of 2 quarters · filed 2022-05-09 | $51.80M derived: sum of 3 quarters · filed 2022-05-09 | $62.74M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $15.52M 10-K · filed 2021-03-12 | $29.93M derived: sum of 2 quarters · filed 2021-11-15 | $40.87M derived: sum of 3 quarters · filed 2021-11-15 | $50.44M 10-K · filed 2023-02-28 |
| 2020-09-30 | $14.41M 10-Q · filed 2021-11-15 | $25.35M derived: sum of 2 quarters · filed 2021-11-15 | $34.91M 10-Q · filed 2021-11-15 | $44.41M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $10.94M 10-Q · filed 2021-08-09 | $20.50M 10-Q · filed 2021-08-09 | $30.01M derived: sum of 3 quarters · filed 2021-08-09 | $39.93M derived: sum of 4 quarters · filed 2021-08-09 |
| 2020-03-31 | $9.56M 10-Q · filed 2021-05-11 | $19.06M derived: sum of 2 quarters · filed 2021-05-11 | $28.99M derived: sum of 3 quarters · filed 2021-05-11 | $41.28M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $9.50M 10-K · filed 2021-03-12 | $19.43M derived: sum of 2 quarters · filed 2021-03-12 | $31.71M derived: sum of 3 quarters · filed 2021-03-12 | $42.99M 10-K · filed 2022-03-01 |
| 2019-09-30 | $9.92M 10-K · filed 2021-03-12 | $22.21M derived: sum of 2 quarters · filed 2021-03-12 | $33.49M 10-Q · filed 2020-11-05 | $49.31M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-06-30 | $12.29M 10-K · filed 2021-03-12 | $23.57M 10-Q · filed 2020-08-06 | $39.39M derived: sum of 3 quarters · filed 2021-03-12 | $53.48M derived: sum of 4 quarters · filed 2021-03-12 |
| 2019-03-31 | $11.28M 10-K · filed 2021-03-12 | $27.10M derived: sum of 2 quarters · filed 2021-03-12 | $41.20M derived: sum of 3 quarters · filed 2021-03-12 | $56.05M derived: sum of 4 quarters · filed 2021-03-12 |
| 2018-12-31 | $15.82M 10-K · filed 2020-03-05 | $29.92M derived: sum of 2 quarters · filed 2020-03-05 | $44.77M derived: sum of 3 quarters · filed 2020-03-05 | $60.11M 10-K · filed 2021-03-12 |
| 2018-09-30 | $14.10M 10-K · filed 2020-03-05 | $28.95M derived: sum of 2 quarters · filed 2020-03-05 | $44.29M 10-Q · filed 2019-11-07 | $60.88M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-06-30 | $14.85M 10-K · filed 2020-03-05 | $30.19M 10-Q · filed 2019-08-07 | $46.79M derived: sum of 3 quarters · filed 2020-03-05 | $58.98M derived: sum of 4 quarters · filed 2020-03-05 |
| 2018-03-31 | $15.34M 10-K · filed 2020-03-05 | $31.94M derived: sum of 2 quarters · filed 2020-03-05 | $44.13M derived: sum of 3 quarters · filed 2020-03-05 | $53.99M derived: sum of 4 quarters · filed 2020-03-05 |
| 2017-12-31 | $16.60M 10-K · filed 2019-03-07 | $28.79M derived: sum of 2 quarters · filed 2019-03-07 | $38.65M derived: sum of 3 quarters · filed 2019-03-07 | $48.20M 10-K · filed 2020-03-05 |
| 2017-09-30 | $12.19M 10-K · filed 2019-03-07 | $22.05M derived: sum of 2 quarters · filed 2019-03-07 | $31.60M 10-Q · filed 2018-11-05 | $40.08M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $9.86M 10-K · filed 2019-03-07 | $19.41M 10-Q · filed 2018-08-08 | $27.89M derived: sum of 3 quarters · filed 2019-03-07 | $40.16M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $9.55M 10-K · filed 2019-03-07 | $18.03M derived: sum of 2 quarters · filed 2019-03-07 | $30.30M derived: sum of 3 quarters · filed 2019-03-07 | $36.43M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $8.47M 10-K · filed 2018-03-08 | $20.75M derived: sum of 2 quarters · filed 2018-03-08 | $26.88M derived: sum of 3 quarters · filed 2018-03-08 | $31.66M 10-K · filed 2019-03-07 |
| 2016-09-30 | $12.27M 10-K · filed 2018-03-08 | $18.41M derived: sum of 2 quarters · filed 2018-03-08 | $23.19M 10-Q · filed 2017-11-08 | $25.78M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $6.13M 10-K · filed 2018-03-08 | $10.92M 10-Q · filed 2017-08-10 | $13.50M derived: sum of 3 quarters · filed 2018-03-08 | $16.47M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $4.79M 10-K · filed 2018-03-08 | $7.37M derived: sum of 2 quarters · filed 2018-03-08 | $10.34M derived: sum of 3 quarters · filed 2018-03-08 | $12.61M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $2.59M 10-K · filed 2017-03-14 | $5.55M derived: sum of 2 quarters · filed 2017-03-14 | $7.83M derived: sum of 3 quarters · filed 2017-03-14 | $9.55M 10-K · filed 2018-03-08 |
| 2015-09-30 | $2.97M 10-K · filed 2017-03-14 | $5.24M derived: sum of 2 quarters · filed 2017-03-14 | $6.96M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $2.27M 10-K · filed 2017-03-14 | $3.99M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $1.72M 10-K · filed 2017-03-14 | |||
| 2014-12-31 | $10.18M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |